NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $27.02 -0.22 (-0.81%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$25.37▼$27.6250-Day Range$20.23▼$27.2452-Week Range$12.54▼$28.20Volume910,747 shsAverage Volume331,563 shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$44.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Bicycle Therapeutics alerts: Email Address Bicycle Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside64.9% Upside$44.56 Price TargetShort InterestHealthy4.42% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 17 Articles This WeekInsider TradingSelling Shares$89,460 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.17) to ($3.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector317th out of 919 stocksPharmaceutical Preparations Industry144th out of 424 stocks 4.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBicycle Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bicycle Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.42% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 4.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 3.0 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Bicycle Therapeutics this week, compared to 4 articles on an average week.Search Interest10 people have searched for BCYC on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,460.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($3.17) to ($3.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bicycle Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Bicycle Therapeutics Stock (NASDAQ:BCYC)Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Read More BCYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCYC Stock News HeadlinesSeptember 14 at 3:00 AM | businesswire.comBicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024September 11, 2024 | yahoo.comConstruction to begin on protected bike lane on Bedford Avenue in BrooklynSeptember 15, 2024 | Crypto 101 Media (Ad)Trader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.September 11, 2024 | markets.businessinsider.comBuy Rating for Bicycle Therapeutics Amid Promising Zelenectide Pevedotin Clinical DataSeptember 11, 2024 | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Rating Reiterated by Cantor FitzgeraldSeptember 11, 2024 | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Rating Reiterated by Needham & Company LLCSeptember 10, 2024 | markets.businessinsider.comBicycle Therapeutics: Outpacing Competitors with Promising Drug Pipeline – A Buy Rating JustifiedSeptember 10, 2024 | americanbankingnews.comBrokerages Set Bicycle Therapeutics plc (NASDAQ:BCYC) PT at $44.56September 15, 2024 | Crypto 101 Media (Ad)Trader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.September 9, 2024 | markets.businessinsider.comBarclays Issues a Buy Rating on Bicycle Therapeutics (BCYC)September 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)September 7, 2024 | americanbankingnews.comBicycle Therapeutics (NASDAQ:BCYC) Now Covered by Analysts at Royal Bank of CanadaSeptember 6, 2024 | benzinga.comIn-Depth Examination Of 5 Analyst Recommendations For Bicycle TherapeuticsSeptember 6, 2024 | msn.comRBC Capital Initiates Coverage of Bicycle Therapeutics plc - Depositary Receipt () (BCYC) with Outperform RecommendationSeptember 6, 2024 | finance.yahoo.comBicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish ToneAugust 30, 2024 | ca.finance.yahoo.comBCYC Oct 2024 30.000 callAugust 30, 2024 | yahoo.comFridrich Bicycle in Ohio City closing soon, after 141 yearsAugust 29, 2024 | ca.finance.yahoo.comBCYC Mar 2025 20.000 putSee More Headlines Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/15/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$44.56 High Stock Price Target$65.00 Low Stock Price Target$28.00 Potential Upside/Downside+64.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,660,000.00 Net Margins-417.88% Pretax Margin-411.92% Return on Equity-32.80% Return on Assets-23.30% Debt Debt-to-Equity Ratio0.01 Current Ratio14.77 Quick Ratio14.77 Sales & Book Value Annual Sales$26.98 million Price / Sales47.57 Cash FlowN/A Price / Cash FlowN/A Book Value$12.35 per share Price / Book2.19Miscellaneous Outstanding Shares47,500,000Free Float39,143,000Market Cap$1.28 billion OptionableOptionable Beta0.90 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Kevin Lee M.B.A. (Age 56)Ph.D., CEO & Executive Director Comp: $1.35MSir Gregory Paul Winter CBE (Age 73)FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director Comp: $57.75kMs. Alethia Rene Young (Age 45)Chief Financial Officer Comp: $581.69kDr. Santiago Arroyo M.D. (Age 64)Ph.D., Chief Development Officer Comp: $916.98kDr. Christian HeinisScientific FounderMr. Alistair Milnes (Age 50)Chief Operating Officer Comp: $796.09kMr. Travis ThompsonSenior VP, Chief Accounting Officer & Principal Accounting OfficerDr. Michael Skynner B.sc. Ph.d. (Age 55)Ph.D., Chief Technology Officer Comp: $881.01kDr. Nicholas Keen Ph.D. (Age 56)Chief Scientific Officer Mr. Zafar QadirGeneral CounselMore ExecutivesKey CompetitorsImmunicNASDAQ:IMUXPieris PharmaceuticalsNASDAQ:PIRSBridgeBio PharmaNASDAQ:BBIOApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 284,094 shares on 8/19/2024Ownership: 0.137%Perceptive Advisors LLCBought 572,000 shares on 8/16/2024Ownership: 1.337%Armistice Capital LLCBought 300,000 shares on 8/15/2024Ownership: 4.610%The Manufacturers Life Insurance Company Bought 71,434 shares on 8/15/2024Ownership: 0.228%HighVista Strategies LLCSold 31,038 shares on 8/14/2024Ownership: 0.297%View All Insider TransactionsView All Institutional Transactions BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $18.08 at the beginning of the year. Since then, BCYC shares have increased by 49.4% and is now trading at $27.02. View the best growth stocks for 2024 here. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.33. The company's quarterly revenue was down 17.9% on a year-over-year basis. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Top institutional shareholders of Bicycle Therapeutics include Armistice Capital LLC (4.61%), First Light Asset Management LLC (3.24%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.08%) and Candriam S.C.A. (1.77%). Insiders that own company stock include Kevin Lee, Michael Skynner, Nicholas Keen, Nigel Crockett, Alistair Milnes, Lee Kalowski, Travis Alvin Thompson, Michael Charles Ferguso Hannay and Pierre Legault. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM) and Agenus (AGEN). This page (NASDAQ:BCYC) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts